According to Tekmira, AlCana is an “instrument of Alnylam” used to “escape the licensing and royalty obligations” of the companies' agreements.
"Tekmira will be responsible for preparing the SNALP formulations and Pfizer will evaluate the formulations in preclinical models," the companies said.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.